Trial Profile

LCCC 1917: Dose Escalation of Low and Intermediate Risk Localized Prostate Cancer Using 68Ga-HBED-CC PSMA-PET/MRI and Stereotactic Body Radiotherapy

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gallium (68Ga) gozetotide (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Diagnostic use
Acronyms LCCC 1917

Most Recent Events

19 Mar 2024 Status changed from suspended to withdrawn prior to enrolment.
31 Jan 2024 Planned End Date changed from 1 May 2028 to 1 May 2029.
31 Jan 2024 Planned primary completion date changed from 1 Oct 2024 to 1 Oct 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com